May 2021

Dear WIPO Re:Search Members and Friends,

We are excited to announce the release of our 2020 WIPO Re:Search Partnership Hub Annual Report. In this report we feature the Consortium’s accomplishments during a year unlike any other—from new international collaborations and significant advances in ongoing collaborations, to expansion of our global Member network and high-profile awards for our Fellowship Program alumni.

World IP Day, celebrated every year on April 26, highlights the critical role that IP plays in encouraging innovation in areas including global health. We are proud of our WIPO Re:Search company Members for deploying their valuable IP assets—on World IP Day and every day—through global partnerships to fight neglected diseases. The work of many of our companies was recently spotlighted in international media, including:

- **Eisai**: An animation showcasing the company’s lymphatic filariasis elimination activities—encompassing medicines delivery to endemic countries and disease awareness programs—won an award at the International Society for Neglected Tropical Diseases (ISNTD) Festival 2021.
- **Novartis**: The company is partnering with Medicines for Malaria Venture to develop two new antimalarial drugs that are in late-stage clinical trials, and is also investigating the repurposing of one of its heart failure drugs for chronic Chagas cardiomyopathy. Additionally, Novartis has renewed an agreement with the World Health Organization to provide access to its leprosy and fascioliasis medicines through the end of 2025.
- **Pfizer**: The elimination of trachoma as a public health problem in The Gambia was made possible through strong partnerships, including broad access to the company’s antibiotic azithromycin.
- **Takeda**: In a new interview with WIPO, Dr. Chris Reddick, Head of Takeda’s R&D Center for Health Equity, highlighted the myriad ways that the company is driving neglected disease R&D innovation through IP-sharing collaborations—including compounds for tuberculosis drug discovery, microneedle patch technology for malaria vaccine development, and knowledge exchange and capacity building.

As always, please share this Snapshot with your colleagues and reach out to us with any partnering requests or ideas.

Sincerely,

Jennifer Dent, President & CEO
BIO Ventures for Global Health

---

Special Announcements

**Input Requested: WIPO Re:Search Performance, 2022-2026 Strategy**

As WIPO Re:Search enters its second decade, the consulting firm everis (NTT Data) is conducting an independent review of the Consortium’s performance (per the 2017-2021 Strategic Plan) and coordinating the development of the 2022-2026...
Strategic Plan. Input from WIPO Re:Search stakeholders—across sectors and geographic regions—is critical for this process. If you have not been contacted by everis to provide your insights and opinions, please click here to access the online survey. Responses are requested no later than May 21, 2021. Please contact Júlia Turon i Lorén at wipo.ReSearch.review@nttdata.com with any questions.

RSTMH Calls for Abstracts for Annual Meeting Due June 7

The Royal Society of Tropical Medicine & Hygiene (RSTMH) is accepting abstracts focused on drug-resistant infections. Poster presentations and five-minute “turbo talks” will be selected from abstracts submitted by early-career researchers. Learn more here.

WIPO Re:Search Statistics

Cornerstones of Collaboration

SSGCID and IP Montevideo Collaborate to Discover New Treatments for Chagas Disease, HAT, and Leishmaniasis

Chagas disease, human African trypanosomiasis (HAT), and leishmaniasis are among the infectious diseases that disproportionately exact a heavy toll on people living in low- and middle-income countries. Dr. Marcelo Comini, Head of the Redox Biology of Trypanosomes Laboratory at the Institut Pasteur de Montevideo (IP Montevideo), works on the discovery of novel drugs targeting the pathogens responsible for these diseases. The Seattle Structural Genomics Center for Infectious Disease (SSGCID), which is contracted through the United States National Institute of Allergy and Infectious Diseases (contract HHSN272201700059C), will investigate the crystal structure of three proteins identified by Dr. Comini to inform rational design of new treatments for Chagas disease, HAT, and leishmaniasis.

IP in Focus

Non-Patent Literature Now Available in PATENTSCOPE

WIPO’s PATENTSCOPE now includes non-patent literature, specifically open access content from some of the world’s leading multidisciplinary science journals on Nature.com. Over 54,000 documents are now searchable in PATENTSCOPE. Access and search PATENTSCOPE here.
BVGH FundFinder Featured Awards

Global Institute for Disease Elimination (GLIDE): Falcon Awards

The Falcon Awards for Disease Elimination were created to help advance the elimination of malaria, polio, lymphatic filariasis, and onchocerciasis. Up to five grants of up to $200,000 each will be awarded to organizations based in endemic countries. Proposals should demonstrate a high potential to expand and amplify effective solutions in disease elimination and create lasting impacts. GLIDE recommends that projects align with national priorities to advance disease elimination strategies, along with international objectives of WHO’s NTD road map. Deadline for abstract submissions is June 13, 2021. For more information, click [here](#).

Additional Funding Opportunities

- [NIH/NIAID Tropical Medicine Research Centers (U01 Clinical Trial Not Allowed)](https://nihroadmap.nih.gov/ntd) for NTDs in endemic areas – Letter of Intent Deadline: May 19, 2021; Application Deadline: June 18, 2021.

For more information about BVGH FundFinder, please email Cathy Manner.

Upcoming Virtual Global Health Events

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>May 25-27, 2021</td>
<td><a href="#">BioMalPar XVII: Biology and Pathology of the Malaria Parasite</a></td>
</tr>
<tr>
<td>June 10, 2021</td>
<td><a href="#">Neglected Tropical Disease Network for NGOs (NNN) Rising to the Challenge: Learning and Adapting NTD Programming in a Changing Landscape</a></td>
</tr>
<tr>
<td>May 31-June 18, 2021</td>
<td><a href="#">6th McGill Summer Institute in Infectious Diseases and Global Health</a></td>
</tr>
<tr>
<td>June 18, 2021</td>
<td><a href="#">RSTMH Topics in Infection 2021</a></td>
</tr>
<tr>
<td>July 12-14, 2021</td>
<td><a href="#">Future Insight Days</a></td>
</tr>
</tbody>
</table>
*The business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics in the US and Canada.
**MSD is a trademark of Merck & Co., Inc., Kenilworth, NJ, USA.